Skip to main content

Table 4 CD56+ cells in primaries and recurrences

From: Quantities of CD3+, CD8+ and CD56+ lymphocytes decline in breast cancer recurrences while CD4+ remain similar

 

CD56 PRIMARY

P

CD56 RECURRENCE

P

SRI

79%

0.003*

38%

0.235

IRI

42%

 

39%

 

LRI

34%

 

21%

 

KI67 ≤20%

41%

0.004*

32%

0.834

KI67>20%

79%

 

32%

 

G1

42%

0.105

21%

0.191

G2

42%

 

27%

 

G3

67%

 

46%

 

DUCTAL

47%

0.498

31%

0.705

LOBULAR

54%

 

36%

 

ER NEGATIVE

56%

0.304

32%

0.984

ER POSITIVE

45%

 

32%

 

PR NEGATIVE

63%

0.056

41%

0.208

PR POSITIVE

41%

 

28%

 

HER2 NEGATIVE

49%

0.780

30%

0.204

HER2 POSITIVE

44%

 

50%

 

SIZE < 20 MM

50%

 

33%

 

SIZE ≥ 20 MM

50%

1.000

33%

1.000

  1. Percentages of tumors with CD56+cells and p-values for significance of differences, SRI Short recurrence interval <2 y, IRI Intermediate recurrence interval 5-10 y, LRI Long recurrence interval >10 y. HER2 Human epidermal growth factor receptor 2, ER Estrogen receptor, PR Progesterone receptor, G Grade. Statistically significant differences within different clinicopathologic factors are marked with *